恩替卡韦治疗慢性乙型肝炎患者免疫功能变化的研究

Objective To investigate the feature of immune function in chronic hepatitis B(CHB) patients with enticarvir (ETV) therapy. Methods The venous blood samples in health controls and CHB patients at different time points after ETV therapy were collected. Serum and PBMCs were isolated, HBV markers, HBV DNA, ALT, serum cytokines and the cytokines were stimulated by CD3/CD28 cells and HBcAg, the frequency of immune cells were detected and compared with pretreatment. Results ALT and HBV DNA levels in patients at the 4th week decreased significantly, which were (73.78 ±93.34) U/L and (3.98 ±0.75)IU/mL respectively (t =3.816,2.795, P< 0.05), and the both returned to normal after 48-week therapy of ETV. IFN γ in serum and two stimulation supernatant decreased significantly compared to baseline after 4-week therapy (t - 2.386,2.358,2.448, P < 0.05). IL-10 level in serum decreased to (78.12 ± 24.01) pg/mL and was still higher than that in the health controls at the 48th week( t = 2.823, P < 0.05). IL-17 in serum and two stimulation supernatant increased significantly compared to baseline at the 4th week (t = 3.580, 2.448,2.464, P<0.05). IL-22 in serum increased to (85.22± 38.37) pg/mL and was still lower than that in health controls at the 4th week 0 = 2.272, p<0.05).The frequency of Th1 and Th17 cells increased significantly at the 4th week (t = 2.386, 2.998, P < 0.05); and then decreased gradually but still higher than that in health controls at the 48th week. The frequency of Th2 cells increased obviously at the 4th week (t = 3.062,P<0.05), and was the highest at the 12th week, then was lower than that in health controls at the 48th week( t = 2.690, P < 0.05) .The frequency of Treg cells decreased to normal after the treatment. Conclusions ETV suppresses HBV replication efficiently, which may attenuate hepatic inflammation but impair the ability of HBV clearing in the disease.     

聚乙二醇干扰素α-2a治疗后乙型肝炎患者外周血Th1与Th2细胞变化

目的 研究聚乙二醇IFN-α2a(Peg-IFN-α2a)治疗后完全应答乙型肝炎患者外周血中Th1与Th2细胞频数变化.方法 抽取应用Peg-IFN-α2a治疗发生完全应答乙型肝炎患者7例、健康对照者9名、未进行治疗的乙型肝炎患者9例的静脉血,分离血清及外周血单核细胞(PMBC),检测血清中HBV标志物、HBV DNA、ALT以及外周血中的CD3+CD4+IFN-γ+T细胞、CD3+CD4+IL-4+T细胞的频数.结果 7例患者发生HBsAg转换的时间最短为36周,最长为49周,平均为(39.28±6.44)周.患者外周血中CD3+CD4+IFN-γ+T细胞的频数表现为持续下降,但6个月后仍高于健康对照;而CD3+CD4+IL-4+T细胞的频数在发生应答的时间点升高,明显低于健康对照,6个月后下降.结论 应用Peg-IFN-α2a治疗后发生完全应答的患者,体内Th1类免疫应答下降而Th2类应答不足,体内仍存在一定程度的炎症反应.     

Clinical study of the efficacy of interferon-α therapy for HBeAg-negative chronic hepatitis B patients

Objective To investigate the effect of IFN-α therapy for HBeAg-negative ehronie hepatitis B(CHB). Methods 50 cases of HBeAg-negative CHB patients were selected as treated group, while 52 cases of HBeAg-positive CHB as control group. Both groups received injection of IFN-α at dose of 6 MU every other day for 48 weeks. Levels of alanine aminotransferase, viral markers levels of HBeAg, HBV DNA and the four serum fibrosis markers were analysed before and after treatment and 24 weeks after the course. Results There were 36 cases in treated group and 26 cases in control group who had got obvious therapeutic effects at the end of 24 weeks after treatment. And the rates of efficacy were 72% and 50% separately. The rate of treated group was higher than that of control group(X2 = 5.43, P <0.05). The four serum fibrosis markers of the both groups were clearly dropped after treatment (t = 2.365, P < 0.05). Conclusions The theraputie effects of IFN-α at dose of 6 MU for HBeAg-negative CHB is prior to HBeAg-positive CHB. And IFN-α also have an evident funtion on preventing or delaying hepatic fibrosis in patients with CHB.     

Clinical study of the efficacy of interferon-α therapy for HBeAg-negative chronic hepatitis B patients

Objective To investigate the effect of IFN-α therapy for HBeAg-negative ehronie hepatitis B(CHB). Methods 50 cases of HBeAg-negative CHB patients were selected as treated group, while 52 cases of HBeAg-positive CHB as control group. Both groups received injection of IFN-α at dose of 6 MU every other day for 48 weeks. Levels of alanine aminotransferase, viral markers levels of HBeAg, HBV DNA and the four serum fibrosis markers were analysed before and after treatment and 24 weeks after the course. Results There were 36 cases in treated group and 26 cases in control group who had got obvious therapeutic effects at the end of 24 weeks after treatment. And the rates of efficacy were 72% and 50% separately. The rate of treated group was higher than that of control group(X2 = 5.43, P <0.05). The four serum fibrosis markers of the both groups were clearly dropped after treatment (t = 2.365, P < 0.05). Conclusions The theraputie effects of IFN-α at dose of 6 MU for HBeAg-negative CHB is prior to HBeAg-positive CHB. And IFN-α also have an evident funtion on preventing or delaying hepatic fibrosis in patients with CHB.     

Clinical study of the efficacy of interferon-α therapy for HBeAg-negative chronic hepatitis B patients

Objective To investigate the effect of IFN-α therapy for HBeAg-negative ehronie hepatitis B(CHB). Methods 50 cases of HBeAg-negative CHB patients were selected as treated group, while 52 cases of HBeAg-positive CHB as control group. Both groups received injection of IFN-α at dose of 6 MU every other day for 48 weeks. Levels of alanine aminotransferase, viral markers levels of HBeAg, HBV DNA and the four serum fibrosis markers were analysed before and after treatment and 24 weeks after the course. Results There were 36 cases in treated group and 26 cases in control group who had got obvious therapeutic effects at the end of 24 weeks after treatment. And the rates of efficacy were 72% and 50% separately. The rate of treated group was higher than that of control group(X2 = 5.43, P <0.05). The four serum fibrosis markers of the both groups were clearly dropped after treatment (t = 2.365, P < 0.05). Conclusions The theraputie effects of IFN-α at dose of 6 MU for HBeAg-negative CHB is prior to HBeAg-positive CHB. And IFN-α also have an evident funtion on preventing or delaying hepatic fibrosis in patients with CHB.     

Clinical study of the efficacy of interferon-α therapy for HBeAg-negative chronic hepatitis B patients

Objective To investigate the effect of IFN-α therapy for HBeAg-negative ehronie hepatitis B(CHB). Methods 50 cases of HBeAg-negative CHB patients were selected as treated group, while 52 cases of HBeAg-positive CHB as control group. Both groups received injection of IFN-α at dose of 6 MU every other day for 48 weeks. Levels of alanine aminotransferase, viral markers levels of HBeAg, HBV DNA and the four serum fibrosis markers were analysed before and after treatment and 24 weeks after the course. Results There were 36 cases in treated group and 26 cases in control group who had got obvious therapeutic effects at the end of 24 weeks after treatment. And the rates of efficacy were 72% and 50% separately. The rate of treated group was higher than that of control group(X2 = 5.43, P <0.05). The four serum fibrosis markers of the both groups were clearly dropped after treatment (t = 2.365, P < 0.05). Conclusions The theraputie effects of IFN-α at dose of 6 MU for HBeAg-negative CHB is prior to HBeAg-positive CHB. And IFN-α also have an evident funtion on preventing or delaying hepatic fibrosis in patients with CHB.     

Clinical study of the efficacy of interferon-α therapy for HBeAg-negative chronic hepatitis B patients

Objective To investigate the effect of IFN-α therapy for HBeAg-negative ehronie hepatitis B(CHB). Methods 50 cases of HBeAg-negative CHB patients were selected as treated group, while 52 cases of HBeAg-positive CHB as control group. Both groups received injection of IFN-α at dose of 6 MU every other day for 48 weeks. Levels of alanine aminotransferase, viral markers levels of HBeAg, HBV DNA and the four serum fibrosis markers were analysed before and after treatment and 24 weeks after the course. Results There were 36 cases in treated group and 26 cases in control group who had got obvious therapeutic effects at the end of 24 weeks after treatment. And the rates of efficacy were 72% and 50% separately. The rate of treated group was higher than that of control group(X2 = 5.43, P <0.05). The four serum fibrosis markers of the both groups were clearly dropped after treatment (t = 2.365, P < 0.05). Conclusions The theraputie effects of IFN-α at dose of 6 MU for HBeAg-negative CHB is prior to HBeAg-positive CHB. And IFN-α also have an evident funtion on preventing or delaying hepatic fibrosis in patients with CHB.     

慢性乙型肝炎患者血清XCL1与免疫损伤的相关性分析

Objective To explore the relevance between serum XCL1 levels and liver damage in hepatitis B patients.Methods The serum concentration of XCL1 was detected by enzyme linked immu-nosorbent assay (ELISA).Peripheral blood T-cell subsets were detected by flow cytometry (FCM).Liver function was assayed by automatic biochemistry analyzer, hepatitis B antigen/antibody semi-quantitative index was detected by time-resolved fluorescence analyzer, and HBV-DNA load was detected by automatic fluorescence quantitative PCR.Results Serum concentration of XCL1 in control group ( n = 20), mild chronic hepatitis B (CHB) group ( n =29), moderate CHB group ( n =20) and severe CHB group ( n =26)were (8.24±1.94) pg/ml, (10.99±1.94) pg/ml, (12.83 ±2.59) pg/ml, (13.72 ±3.13) pg/ml,respectively.The concentration of XCL1 in all CHB groups was significantly higher than control group ( P＜ 0.05 ).The concentration of XCL1 in severe CHB group was significantly higher than mild CHB group (P ＜ 0.05).XCL1 was positively correlated with ALT, AST, TBIL and DBIL, and the coefficients were (r =0.463、 0.472、 0.413、 0.440, P ＜0.01 ), respectively.The serum XCL1 levels in hepatitis B virus with low load group was lower than hepatitis B virus with high load group.The percentage of CD4 + T in hepatitis B virus with low load group and high load group were (41.26 ± 11.33)%, (33.01 ± 5.96)%,and the difference was statistically significant.Conclusion Serum concentrations of XCL1 were closely related to the degree of liver inflammation in hepatitis B patients.XCL1 may be involved in the process of chronic hepatitis B.     

慢性乙型肝炎患者血清XCL1与免疫损伤的相关性分析

Objective To explore the relevance between serum XCL1 levels and liver damage in hepatitis B patients.Methods The serum concentration of XCL1 was detected by enzyme linked immu-nosorbent assay (ELISA).Peripheral blood T-cell subsets were detected by flow cytometry (FCM).Liver function was assayed by automatic biochemistry analyzer, hepatitis B antigen/antibody semi-quantitative index was detected by time-resolved fluorescence analyzer, and HBV-DNA load was detected by automatic fluorescence quantitative PCR.Results Serum concentration of XCL1 in control group ( n = 20), mild chronic hepatitis B (CHB) group ( n =29), moderate CHB group ( n =20) and severe CHB group ( n =26)were (8.24±1.94) pg/ml, (10.99±1.94) pg/ml, (12.83 ±2.59) pg/ml, (13.72 ±3.13) pg/ml,respectively.The concentration of XCL1 in all CHB groups was significantly higher than control group ( P＜ 0.05 ).The concentration of XCL1 in severe CHB group was significantly higher than mild CHB group (P ＜ 0.05).XCL1 was positively correlated with ALT, AST, TBIL and DBIL, and the coefficients were (r =0.463、 0.472、 0.413、 0.440, P ＜0.01 ), respectively.The serum XCL1 levels in hepatitis B virus with low load group was lower than hepatitis B virus with high load group.The percentage of CD4 + T in hepatitis B virus with low load group and high load group were (41.26 ± 11.33)%, (33.01 ± 5.96)%,and the difference was statistically significant.Conclusion Serum concentrations of XCL1 were closely related to the degree of liver inflammation in hepatitis B patients.XCL1 may be involved in the process of chronic hepatitis B.     

Clinical study of the efficacy of interferon-α therapy for HBeAg-negative chronic hepatitis B patients

Objective To investigate the effect of IFN-α therapy for HBeAg-negative ehronie hepatitis B(CHB). Methods 50 cases of HBeAg-negative CHB patients were selected as treated group, while 52 cases of HBeAg-positive CHB as control group. Both groups received injection of IFN-α at dose of 6 MU every other day for 48 weeks. Levels of alanine aminotransferase, viral markers levels of HBeAg, HBV DNA and the four serum fibrosis markers were analysed before and after treatment and 24 weeks after the course. Results There were 36 cases in treated group and 26 cases in control group who had got obvious therapeutic effects at the end of 24 weeks after treatment. And the rates of efficacy were 72% and 50% separately. The rate of treated group was higher than that of control group(X2 = 5.43, P <0.05). The four serum fibrosis markers of the both groups were clearly dropped after treatment (t = 2.365, P < 0.05). Conclusions The theraputie effects of IFN-α at dose of 6 MU for HBeAg-negative CHB is prior to HBeAg-positive CHB. And IFN-α also have an evident funtion on preventing or delaying hepatic fibrosis in patients with CHB.     

Clinical study of the efficacy of interferon-α therapy for HBeAg-negative chronic hepatitis B patients

Objective To investigate the effect of IFN-α therapy for HBeAg-negative ehronie hepatitis B(CHB). Methods 50 cases of HBeAg-negative CHB patients were selected as treated group, while 52 cases of HBeAg-positive CHB as control group. Both groups received injection of IFN-α at dose of 6 MU every other day for 48 weeks. Levels of alanine aminotransferase, viral markers levels of HBeAg, HBV DNA and the four serum fibrosis markers were analysed before and after treatment and 24 weeks after the course. Results There were 36 cases in treated group and 26 cases in control group who had got obvious therapeutic effects at the end of 24 weeks after treatment. And the rates of efficacy were 72% and 50% separately. The rate of treated group was higher than that of control group(X2 = 5.43, P <0.05). The four serum fibrosis markers of the both groups were clearly dropped after treatment (t = 2.365, P < 0.05). Conclusions The theraputie effects of IFN-α at dose of 6 MU for HBeAg-negative CHB is prior to HBeAg-positive CHB. And IFN-α also have an evident funtion on preventing or delaying hepatic fibrosis in patients with CHB.     

Clinical study of the efficacy of interferon-α therapy for HBeAg-negative chronic hepatitis B patients

Objective To investigate the effect of IFN-α therapy for HBeAg-negative ehronie hepatitis B(CHB). Methods 50 cases of HBeAg-negative CHB patients were selected as treated group, while 52 cases of HBeAg-positive CHB as control group. Both groups received injection of IFN-α at dose of 6 MU every other day for 48 weeks. Levels of alanine aminotransferase, viral markers levels of HBeAg, HBV DNA and the four serum fibrosis markers were analysed before and after treatment and 24 weeks after the course. Results There were 36 cases in treated group and 26 cases in control group who had got obvious therapeutic effects at the end of 24 weeks after treatment. And the rates of efficacy were 72% and 50% separately. The rate of treated group was higher than that of control group(X2 = 5.43, P <0.05). The four serum fibrosis markers of the both groups were clearly dropped after treatment (t = 2.365, P < 0.05). Conclusions The theraputie effects of IFN-α at dose of 6 MU for HBeAg-negative CHB is prior to HBeAg-positive CHB. And IFN-α also have an evident funtion on preventing or delaying hepatic fibrosis in patients with CHB.     

Clinical study of the efficacy of interferon-α therapy for HBeAg-negative chronic hepatitis B patients

Objective To investigate the effect of IFN-α therapy for HBeAg-negative ehronie hepatitis B(CHB). Methods 50 cases of HBeAg-negative CHB patients were selected as treated group, while 52 cases of HBeAg-positive CHB as control group. Both groups received injection of IFN-α at dose of 6 MU every other day for 48 weeks. Levels of alanine aminotransferase, viral markers levels of HBeAg, HBV DNA and the four serum fibrosis markers were analysed before and after treatment and 24 weeks after the course. Results There were 36 cases in treated group and 26 cases in control group who had got obvious therapeutic effects at the end of 24 weeks after treatment. And the rates of efficacy were 72% and 50% separately. The rate of treated group was higher than that of control group(X2 = 5.43, P <0.05). The four serum fibrosis markers of the both groups were clearly dropped after treatment (t = 2.365, P < 0.05). Conclusions The theraputie effects of IFN-α at dose of 6 MU for HBeAg-negative CHB is prior to HBeAg-positive CHB. And IFN-α also have an evident funtion on preventing or delaying hepatic fibrosis in patients with CHB.     

急性乙型肝炎临床特征和病毒标志物动态变化分析

Objective To explore the dynamic change of viral marker and clinical features in acute hepatitis B (AHB)and distinguish AHB from chronic hepatitis B(CHB) in acute onset. Methods Viral marker, HBV DNA in serum and clinical features were analyzed in 105 patients with AHB (AHB group) and 102 patients with CHB in acute onset (CHB group) between 2005 and 2009. Results There was no statistical difference in the mean levels of ALT, TBil, HBsAg, HBeAg and HBV DNA between AHB and CHB group on admission. However, the titer of auti-HBc-IgM in AHB group was(26.34 ±3.74)S/CO, which was obviously higher than that in CHB group, which was( 14.46 ± 3.10)S/CO, there was a statistical difference between the two groups( P < 0.05). After 2 weeks treatment, the levels of ALT and TBil in AHB patients decreased (1540.50±225.54)IU/L and (103.60± 46.48) μmol/L respectively, the decreased levels in AHB group were high compared to CHB group; the levels of HBsAg, HBeAg and HBV DNA in AHB group decreased (2558.46 ±644.26) IU/mL, (420.20± 63.20) S/CO and (4.53± 1.42) log10copies/mL respectively, and the levels decreased obviously compared to CHB group (P < 0.05). The decreased level of anti-HBc-IgM in AHB group was no statistical difference to CHB group after 2 weeks treatment (P > 0.05). 19.04% of the AHB patients were HBV DNA negative seroconversion before they were hospitalized. The level of HBsAg and HBeAg in AHB group declined quickly. Separately, 90.47% and 94.24% of the AHB patients had HBsAg and HBeAg seroconversion at the end of follow-up in AHB group. The level of ALT in AHB decreased quickly but its normalization was slower than the clearance of HBV. Conclusions There is no difference in viral marker, HBV DNA and clinical features between AHB and CHB in acute onset patients on admission, but the recovery of liver function in AHB is obviously after treatment. Anti-HBc-IgM (≥20 S/CO), dynamic change and seroconversion viral marker, ALT ≥20×ULN and recovery can be used to differentiate AHB from CHB in acute onset.     

急性乙型肝炎临床特征和病毒标志物动态变化分析

Objective To explore the dynamic change of viral marker and clinical features in acute hepatitis B (AHB)and distinguish AHB from chronic hepatitis B(CHB) in acute onset. Methods Viral marker, HBV DNA in serum and clinical features were analyzed in 105 patients with AHB (AHB group) and 102 patients with CHB in acute onset (CHB group) between 2005 and 2009. Results There was no statistical difference in the mean levels of ALT, TBil, HBsAg, HBeAg and HBV DNA between AHB and CHB group on admission. However, the titer of auti-HBc-IgM in AHB group was(26.34 ±3.74)S/CO, which was obviously higher than that in CHB group, which was( 14.46 ± 3.10)S/CO, there was a statistical difference between the two groups( P < 0.05). After 2 weeks treatment, the levels of ALT and TBil in AHB patients decreased (1540.50±225.54)IU/L and (103.60± 46.48) μmol/L respectively, the decreased levels in AHB group were high compared to CHB group; the levels of HBsAg, HBeAg and HBV DNA in AHB group decreased (2558.46 ±644.26) IU/mL, (420.20± 63.20) S/CO and (4.53± 1.42) log10copies/mL respectively, and the levels decreased obviously compared to CHB group (P < 0.05). The decreased level of anti-HBc-IgM in AHB group was no statistical difference to CHB group after 2 weeks treatment (P > 0.05). 19.04% of the AHB patients were HBV DNA negative seroconversion before they were hospitalized. The level of HBsAg and HBeAg in AHB group declined quickly. Separately, 90.47% and 94.24% of the AHB patients had HBsAg and HBeAg seroconversion at the end of follow-up in AHB group. The level of ALT in AHB decreased quickly but its normalization was slower than the clearance of HBV. Conclusions There is no difference in viral marker, HBV DNA and clinical features between AHB and CHB in acute onset patients on admission, but the recovery of liver function in AHB is obviously after treatment. Anti-HBc-IgM (≥20 S/CO), dynamic change and seroconversion viral marker, ALT ≥20×ULN and recovery can be used to differentiate AHB from CHB in acute onset.     

拉米夫定联合阿德福韦酯与恩替卡韦治疗慢性乙型肝炎疗效比较

Objective To analyze the effect of lamivudine combined with adefovir and entecavir in treatment of chronic hepatitis B patients, to provide the basis for felicitous treatment. Methods 120 cases of chronic hepatitis B patients were divided into two groups(lamivudine combined with adefovir group and entecavir group) according to the method of treatment. The clinical data of two groups were recorded, including the cases of ALT normalization, HBeAg negative conversion and HBV DNA below to the detection level in different treatment time. Results After 3, 6, 12 months of treatment, there was no statistical difference between the two groups in ALT normalization ( x2 = 2.194,2.353,3.339, P＞ 0.05); and there was no statistical difference in the incidence of HBeAg negative after 3,6,12.18 months of treatment too(x2 = 0.054,0.139,0.326,0.152, P ＞ 0.05). There was no statistical difference in the incidence of HBV DNA returned to nagative after 6,12, 18,24 months trentment ( x2 = 0.348,0.348,2.236,0.776, P ＞ 0.05). Conclusions There was no difference in the ALT normalization, the incidence of HBeAg negative conversion and the incidence of HBV DNA retumed to nagative in lamivudine combined with adefovir and entecavir for chronic hepatitis B.     

Th1/Th2细胞表面标志的研究进展

根据所分泌细胞因子的不同,CD4~+Th细胞可分为Ta0、Th1、Th2和Th3四种亚群。Th1/Th2细胞的调节对维持机体正常的免疫功能至关重要。不少研究提出了Th1/Th2细胞的特异性表面标志,本文就这些表面标志近几年来的研究进展作一综述。     

青春双歧杆菌和嗜酸乳酸杆菌对急性期和恢复期结肠炎小鼠Th1/Th2亚群的影响

Objective To observe and analyze the effect of B. Adolescentis and L. Acidophilus on the proportion of Th cell Th1/Th2 in peripheral blood of UC-mice in acute stage and recovery stage. Method 40 BABL/c mice were induced by 3% DSS water for 7 clays free drinking and then with distilled water for 10 days. They were randomly allocated in 4 groups: NS group, SASP group, BF0624 group and LT0637 group, also the fifth group-10 normal animals. The blood of mice were collected by removing their eyes at day 8 and day 18, and then the mononuclear cells were iso]atecl. The proportion of Th1/Th2 was analyze through flow eytometry,hy labeling the specific antibody ot Th cellular membrane with the CD4 antibody, and the cytoplastie antigen of Thl or Th2 with IIA antibody or IF'N-γ antibody. Result The proportion of Th1/Th2 in normal mouse was 0. 84 -0. 94,and it raised up in DSS-mice at both acute stage and recovery stage. It decreased unequally after 7 or 17 days'B, adoleseentis, L. Acidophilus and SASP treatment, but that of all three groups were lower than NS group (2.21±0. 83). Even the proportion got close to the normal animals after 17 days'L. Acidophilus -treated. Conclusion The proportion of Thl/Th2 increased at the acute stage and recovery stage of DSS-mice. Both B. Adoleseentis and L. Acidophilus had more effective than SASP on decreasing the proportion of Th1/Th2 at two stages,ospecially L. Acidophilus.     

青春双歧杆菌和嗜酸乳酸杆菌对急性期和恢复期结肠炎小鼠Th1/Th2亚群的影响

Objective To observe and analyze the effect of B. Adolescentis and L. Acidophilus on the proportion of Th cell Th1/Th2 in peripheral blood of UC-mice in acute stage and recovery stage. Method 40 BABL/c mice were induced by 3% DSS water for 7 clays free drinking and then with distilled water for 10 days. They were randomly allocated in 4 groups: NS group, SASP group, BF0624 group and LT0637 group, also the fifth group-10 normal animals. The blood of mice were collected by removing their eyes at day 8 and day 18, and then the mononuclear cells were iso]atecl. The proportion of Th1/Th2 was analyze through flow eytometry,hy labeling the specific antibody ot Th cellular membrane with the CD4 antibody, and the cytoplastie antigen of Thl or Th2 with IIA antibody or IF'N-γ antibody. Result The proportion of Th1/Th2 in normal mouse was 0. 84 -0. 94,and it raised up in DSS-mice at both acute stage and recovery stage. It decreased unequally after 7 or 17 days'B, adoleseentis, L. Acidophilus and SASP treatment, but that of all three groups were lower than NS group (2.21±0. 83). Even the proportion got close to the normal animals after 17 days'L. Acidophilus -treated. Conclusion The proportion of Thl/Th2 increased at the acute stage and recovery stage of DSS-mice. Both B. Adoleseentis and L. Acidophilus had more effective than SASP on decreasing the proportion of Th1/Th2 at two stages,ospecially L. Acidophilus.